| |
Join our trial design experts on Thursday, May 8 for an insightful webinar on the optimal use cases of master protocols in clinical trials. Register now.
|
|
Today’s Big NewsApr 29, 2025 |
|
Tuesday, May 6, 2025 | 9am ET / 6am PT This webinar will explore how to use AI-driven tools for timely data-driven decisions that are critical to securing approvals, expediting market entry and sustaining competitive strength. Register now.
|
|
| By Ben Adams Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed oligonucleotide therapies from Creyon Bio. |
|
|
|
By Gabrielle Masson An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been delayed—again—this time, with no new decision date given. |
By Ben Adams AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear-out. |
By Nick Paul Taylor Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs. |
|
Get a head start on your IND submission. Lonza's rapid tox offering cuts toxicology material delivery times by up to 50%, overcoming critical bottlenecks. Learn how to streamline your development and hear about our new exciting offering for bispecifics in this webinar.
|
|
By Nick Paul Taylor Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after deprioritizing its lead program and running into unresolved biology questions. |
By Zoey Becker The company's shares jumped nearly 10% as of Monday afternoon, a welcome reprieve after the company's withdrawn bid for a European marketing authorization sparked concern among investors. |
By Gabrielle Masson The Department of Health and Human Services has lifted a stop work order on Vaxart’s phase 2b trial testing out an investigational COVID-19 vaccine pill, with the biotech resuming plans to enroll participants for the 10,000-person study. |
By Darren Incorvaia Dutch biotech Prilenia Therapeutics has entered a licensing pact with Spanish pharmaceutical company Ferrer to push the biotech's sole asset through clinical development and beyond in Europe. |
By Eric Sagonowsky Abeona is gearing up for a third-quarter launch of its new topical gene therapy after an FDA approval. |
By Conor Hale Three Democrats called for an investigation into brain-computer interface devices, to make sure the data they collect is not simply sold for profit. |
Fierce podcastsDon’t miss an episode |
| | Two journalists, one name and a candid conversation—Angus Liu and Angus Chen talk cancer reporting, racial identity and being mistaken for each other. |
|
|---|
|
|
|
Available On-Demand Commissioning and qualification (C&Q) is vital within pharma manufacturing. View this valuable webinar on-demand to explore key strategies for effective management of systems, equipment and processes to ensure product safety, regulatory compliance, operational efficiency and overall quality assurance.
|
|
| eBookTypical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| WhitepaperIs your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
| Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
